Posted on 3/14/18
Johnson & Johnson SEC Filing - Proxy Statement (definitive) (DEF 14A) March 14, 2018
Johnson & Johnson (JNJ)
Posted on 3/27/18
Interview with Chris Cashman, Chairman and CEO of Marinus Pharmaceuticals - Part III
Brought to you by Newmark Knight Frank
Posted on 3/21/18
Interview with Chris Cashman, Chairman and CEO of Marinus Pharmaceuticals - Part II
Brought to you by Newmark Knight Frank
Posted on 3/16/18
Interview with Chris Cashman, Chairman and CEO of Marinus Pharmaceuticals - Part I
Brought to you by Newmark Knight Frank
Posted on 3/14/18
Is Celldex Therapeutics Stock About to Skyrocket?
March has been a good month so far for Celldex Therapeutics (NASDAQ:CLDX) shareholders. The stock is up more than 20% this month, including a big jump . . .
Posted on 3/13/18
AvaCare Medical Announces Expansion Into Hospital And Nursing Home Industry
AvaCare Medical, one of the nation's largest medical supply and equipment companies servicing the home bound patient and their caregivers, has recently announced its expansion into . . .
Posted on 3/13/18
SCYNEXIS Provides Company Update
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today reported financial results for the year ended December . . .
Posted on 3/13/18
Johnson & Johnson Versus Pfizer: Which One Is The Better Income Investment?
The healthcare industry is not cyclical, therefore companies in this industry tend to perform well operationally, even in times when the economy is not very strong. . . .
Posted on 3/13/18
Pfizer Stock Split History
Pfizer (NYSE:PFE) has brought several game-changing medicines to market since its inception more than a century ago. Some of the best-selling drugs in history are Pfizer . . .
Posted on 3/12/18
Windtree and Eleison Announce Collaboration
Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, and Eleison Pharmaceuticals, Inc., a specialty pharmaceutical company . . .
Posted on 3/12/18
AgroFresh’s Harvista Obtains Expanded Label for Cherry Crops
PHILADELPHIA, March 12, 2018 (GLOBE NEWSWIRE) -- AgroFresh Solutions, Inc.(NASDAQ:AGFS), a global leader in produce freshness solutions, today announced that the label for its Harvista™ pre-harvest . . .
Posted on 3/12/18
Biogen To Acquire Mid-Stage Asset From Pfizer For $590M
Biogen Inc. (Nasdaq: BIIB) announced today an agreement to acquire from Pfizer Inc. (NYSE: PFE) PF-04958242, a first-in-class
Posted on 3/9/18
Johnson & Johnson: Fairly Priced Based On 3 Valuation Approaches
Johnson & Johnson (JNJ) holds a leadership position across multiple healthcare segments, including pharmaceuticals, medical devices, and over-the-counter consumer products. This helps JNJ consistently create impressive . . .
Posted on 3/9/18
Merck (MRK) Teams Up With Eisai (ESALY) To Commercialize Cancer Med Lenvima - Slideshow
The following slide deck was published by Merck & Co Inc. in conjunction with this event. 111READ FULL ARTICLE HERE
Posted on 3/9/18
Celldex Therapeutics Finishes 2017 With Plenty of Cash and High Hopes
It's not your standard earnings release when a clinical-stage biotech announces a quarterly update. Usually, financial results aren't nearly as important as pipeline news. That was . . .
Posted on 3/8/18
Merck & Co. Needs A Pipeline Boost As It Eyes Future Acquisitions
Merck & Co. (MRK) has been making many strides in Immuno-Oncology (I-O) by continually expanding the indications for its blockbuster drug KEYTRUDA but investors want to . . .
Posted on 3/8/18
Aevi Genomic Medicine Expands Collaboration with Kyowa Hakko Kirin
Aevi Genomic Medicine, Inc. (NASDAQ MKT: GNMX) today announced that it has expanded its collaboration with Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) with the . . .
Posted on 3/7/18
Celldex Provides Corporate Update
HAMPTON, N.J., March 07, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December . . .
Posted on 3/7/18
Trevena Reports Full Year 2017 Earnings
CHESTERBROOK, Pa., March 07, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced financial results for the fourth quarter and full year ended December 31, 2017 . . .
Posted on 3/7/18
Johnson & Johnson: The Iconic Health Care Brand Is Attractive
Johnson & Johnson (JNJ) is the largest major drug manufacturer, with a market cap of $355 billion. It is also expensive: out of 28 major drug . . .
Posted on 3/6/18
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WAYNE, Pa., March 06, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies . . .
Posted on 3/6/18
Johnson & Johnson: Upside Available If You're Willing To Take On Some Risks
Johnson & Johnson (JNJ) engages in the research and development, manufacture and sale of a range of products in the healthcare industry. They are well diversified . . .
Posted on 3/6/18
Celgene Vs. Biogen: Both Are A Steal, But Which One Is Better?
Today, we are going to take a look at Celgene (CELG) and Biogen (BIIB), two comparable biopharmaceutical companies with a market capitalization of $67 billion and . . .
Posted on 3/6/18
Celgene Announces Expiration of Cash Tender Offer for Shares of Juno Therapeutics
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Juno Therapeutics, . . .
Posted on 3/6/18
SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants
SCYNEXIS, Inc. (Nasdaq: SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of . . .

